Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

The utility of thromboelastography for guiding recombinant activated factor VII therapy for refractory hemorrhage after cardiac surgery.

Wasowicz M, Meineri M, McCluskey SM, Mitsakakis N, Karkouti K.

J Cardiothorac Vasc Anesth. 2009 Dec;23(6):828-34. doi: 10.1053/j.jvca.2009.03.012.

PMID:
19467888
2.

Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.

Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J.

Ann Thorac Surg. 2006 Mar;81(3):875-9.

PMID:
16488687
3.

Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?

Okonta KE, Edwin F, Falase B.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):690-4. Review.

4.

Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery.

Rao VK, Lobato RL, Bartlett B, Klanjac M, Mora-Mangano CT, Soran PD, Oakes DA, Hill CC, van der Starre PJ.

J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1221-6. doi: 10.1053/j.jvca.2014.04.015.

PMID:
25281040
5.

Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.

Tatoulis J, Theodore S, Meswani M, Wynne R, Hon-Yap C, Powar N.

Interact Cardiovasc Thorac Surg. 2009 Sep;9(3):459-62. doi: 10.1510/icvts.2009.204735.

6.

Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis.

Tritapepe L, De Santis V, Vitale D, Nencini C, Pellegrini F, Landoni G, Toscano F, Miraldi F, Pietropaoli P.

Crit Care Med. 2007 Jul;35(7):1685-90.

PMID:
17522585
7.

Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).

Tanaka KA, Taketomi T, Szlam F, Calatzis A, Levy JH.

Anesth Analg. 2008 Mar;106(3):732-8, table of contents. doi: 10.1213/ane.0b013e318163fc76.

PMID:
18292410
8.

Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.

Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH.

Ann Thorac Surg. 2006 Nov;82(5):1779-83.

PMID:
17062247
9.

Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patients.

Lee AI, Campigotto F, Rawn JD, Neuberg D, Kaufman RM, Berliner N.

Br J Haematol. 2012 May;157(3):397-400. doi: 10.1111/j.1365-2141.2011.08992.x. No abstract available.

PMID:
22224596
10.

Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.

Gelsomino S, Lorusso R, Romagnoli S, Bevilacqua S, De Cicco G, Billè G, Stefàno P, Gensini GF.

Eur J Cardiothorac Surg. 2008 Jan;33(1):64-71.

PMID:
17996457
11.

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Ann Thorac Surg. 2008 Mar;85(3):836-44. doi: 10.1016/j.athoracsur.2007.06.076.

PMID:
18291152
12.

The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Pychyńska-Pokorska M, Moll JJ, Krajewski W, Jarosik P.

Pediatr Crit Care Med. 2004 May;5(3):246-50.

PMID:
15115562
13.

Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.

von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, Spies C.

Crit Care Med. 2005 Oct;33(10):2241-6.

PMID:
16215377
14.

Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.

Chapman AJ, Blount AL, Davis AT, Hooker RL.

Eur J Cardiothorac Surg. 2011 Dec;40(6):1314-8; discussion 1318-9. doi: 10.1016/j.ejcts.2011.03.048.

PMID:
21601468
15.

Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).

Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP.

Eur J Cardiothorac Surg. 2011 Dec;40(6):1320-7. doi: 10.1016/j.ejcts.2011.03.032.

PMID:
21550261
16.

Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ.

J Cardiothorac Vasc Anesth. 2011 Dec;25(6):987-94. doi: 10.1053/j.jvca.2011.05.012.

PMID:
21835642
17.

Thromboelastography is a suboptimal test for determination of the underlying cause of bleeding associated with cardiopulmonary bypass and may not predict a hypercoagulable state.

Welsh KJ, Padilla A, Dasgupta A, Nguyen AN, Wahed A.

Am J Clin Pathol. 2014 Oct;142(4):492-7. doi: 10.1309/AJCPVB73TMIDFNCB.

18.

[The use of recombinant activated factor VII for blood loss after cardiovascular surgery].

Gong ZY, Gao CQ, Xiao CS, Li BJ, Ma XH, Zhang CM.

Zhonghua Wai Ke Za Zhi. 2008 Oct 1;46(19):1497-501. Chinese.

PMID:
19094631
19.

Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation.

Hendriks HG, Meijer K, de Wolf JT, Porte RJ, Klompmaker IJ, Lip H, Slooff MJ, van der Meer J.

Blood Coagul Fibrinolysis. 2002 Jun;13(4):309-13.

PMID:
12032396
20.

Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.

Mitsiakos G, Papaioannou G, Giougi E, Karagianni P, Garipidou V, Nikolaidis N.

J Pediatr Hematol Oncol. 2007 Mar;29(3):145-50.

PMID:
17356391
Items per page

Supplemental Content

Support Center